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Although there has been an enormous amount of progress
in dissecting the cellular and molecular mechanisms
underlying bullous pemphigoid (BP), our knowledge regard-
ing the factors affecting risk and prognosis is still very
limited. Historically, it has been taught that the prognosis of
patients with BP is much better than patients diagnosed
with pemphigus, particularly pemphigus vulgaris with
mortality rates of about 25% for untreated patients with
BP and of about 95% for untreated patients with pemphigus
vulgaris (Lever, 1965). Over the past decade, several large
European studies of patients with BP (Roujeau et al, 1998;
Joly et al, 2002; Rzany et al, 2002) demonstrated that even
with treatment, patients with BP have a prognosis as grim
as a diagnosis of end stage heart disease, with more than
40% of patients dying within 12 months.
Based upon these studies in France and Germany, a
reassessment of our therapeutic approaches to BP has
been appropriately suggested. However, the reported
mortality rates in European studies are at odds with reports
from the United States and Great Britain, where 1-year
mortality rates are substantially lower. In this issue of the
Journal, Fairley et al report on their experience with newly
diagnosed patients with BP at the Medical College of
Wisconsin. In this study, they found a 1-year mortality of
11%, much lower than the mortality reported in recent
French and German studies.
While one of us has speculated that the differences in BP
mortality rates between studies could be due to selection
bias for sicker patients seen at referral centers (Korman,
1998), the data presented in this Journal report fail to
support this contention. Although the number of patients
seen was smaller, these patients were also seen in a major
referral center and appear to be similar in terms of age and
co-morbidities. As pointed out by the authors, it is certainly
possible that the differences in mortality rates could be due
to differences in ethnicity. The authors have carefully
examined other potential variables and have identified a
major difference in patient management. At European
referral centers, patients with BP are almost always
hospitalized at the time of diagnosis. In contrast, at the
University of Wisconsin Medical Center, patients are only
rarely admitted to the hospital for management of BP, a
practice pattern that has been widely adopted in the United
States. At first blush, it is hard to imagine that hospitaliza-
tion can explain such large discrepancies in mortality,
particularly when hospitalization may be linked to such
poor outcomes. Hospitals should be places where sick
patients go to heal. However, like all interventions,
hospitalization has risks, the most striking being infection,
a risk that appears to be magnified with age and com-
pounded by immunosuppression. Support for this concept
is found in the study evaluating the prognosis of BP patients
treated with oral vs topical corticosteroids (Joly et al, 2002).
Patients treated with topical steroids had shortened hospital
stays and significantly lower mortality rates (1 year mortality
24%), than did patients treated with systemic steroids who
had lengthened hospital stays and higher mortality rates
(1 year mortality 42%).
Several studies have evaluated factors that may con-
tribute to the prognosis of BP patients with differing results.
Two studies, from Greece and Great Britain, were unable to
identify any clinical features that could prospectively identify
particular subgroups of BP patients with predictable out-
comes (Venning and Wojnarowska, 1992; Kyriakis et al,
1999). In contrast two studies from Germany and France
found that old age generally decreased health and patients
treated with higher dosages of oral steroids had a poorer
prognosis (Roujeau et al, 1998; Rzany et al, 2002). Two other
studies, from France and Japan, found that patients with
circulating antibodies directed against BPAG2 have a
poorer prognosis with an increased likelihood of dying and
tend to have more severe disease requiring higher doses of
systemic corticosteroids (Tanaka et al, 1996; Bernard et al,
1997).
The study presented in the Journal has limitations. It was
not a prospective study, the numbers of patients studied
were modest and, although the patient demographics are
similar to patients previously reported in studies from
France and Germany, the authors did not examine all the
disease management differences. Despite these limitations,
the differences in mortality rates between the present study
and recent German and French studies are striking. Where
does this leave us in terms of our understanding of the
prognosis of BP and our management recommendations?
The collection of data from US centers must be expanded
to provide definitive confirmation or refutation of the
substantially better outcomes that appear to occur in the
US. Larger retrospective studies would be very valuable.
Multicenter collaborative studies performed in a prospective
fashion would allow us to delineate prognostic factors and
death rates in patients with BP. These studies shouldAbbreviation: BP, bullous pemphigoid
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include a comparison of outcomes patients with BP
managed as outpatients or inpatients and could also
include the measurement of BP antigen profiles to deter-
mine prospectively if the presence of BPAG2 antibodies
correlates with risk for more severe disease. The results
of such studies would help to determine whether the risks
inherent in hospitalization could be a confounding variable
that helps to explain the large observed differences in
mortality rates. If non-pharmacological interventions are the
sources of two- to four-fold differences in mortality, any
modest differences in drug management may not become
apparent, even with the otherwise best controlled studies.
Recommendation of standards of practice in the manage-
ment of BP may actually result in worse outcomes if all the
major variables are not recognized.
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